Children with hematologic malignancies continue to exhibit increased IPD risk despite an overall decline in pediatric IPD after the introduction of the PCV13 vaccine.

The introduction of immune checkpoint inhibitors is linked to growing disparity for those with private insurance vs those without insurance.

Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.